Dr. Ron Peck serves as Chief Medical Officer at Arvinas. Dr. Peck brings more than 20 years of clinical and drug development experience to this role. Prior to joining Arvinas, he served as Senior Vice President, Clinical Research at Tesaro, where he oversaw all clinical development efforts for the company’s entire pipeline, including Zejula® (niraparib) and Tesaro’s immuno-oncology programs.
Dr. Peck served as the CMO of Kolltan Pharmaceuticals, a privately held clinical-stage biotechnology company, where he oversaw the clinical development of monoclonal antibodies targeting receptor tyrosine kinases. Dr. Peck also worked at Bristol Myers Squibb (BMS), where he spent 15 years in drug development, eventually serving as Vice President, YERVOY® (ipilimumab) Global Development Lead. At BMS, he played a key role in the approval and commercialization of YERVOY® (ipilimumab) across all indications and contributed to the successful development of multiple other oncology assets, including IXEMPRA® (ixabepilone). Early in his BMS career, Dr. Peck contributed to the life cycle development of ABILIFY® (aripiprazole) within the neuroscience clinical research organization.
Dr. Peck received his bachelor’s degree in Chemistry from Georgetown University, his M.D. from Thomas Jefferson University Medical College, and completed a residency and hematology/oncology fellowship at Georgetown University before serving as Assistant Professor of Medicine at the University of Virginia.
You are now leaving arvinas.com. Arvinas does not endorse or recommend the content in any third-party sites. Arvinas is not responsible and disclaims liability for the content, or for any viruses or similar harmful programs, that may be present on third-party pages or sites. Visits to a third-party website are at your own risk and subject to the terms and conditions and privacy policy of such site.
